CAP™ : a novel Fibroscan-based diagnostic tool to assess liver steatosis

admin isbra esbra

Sasso, M1; Miette, V1; Sandrin, L1

1R&D department, Echosens, Paris, France

Introduced in 2003, Vibration-Controlled Transient Elastography (Fibroscan®, Echosens, France) disruptive technology is now widely used in routine clinical practice and research. Indeed, a large body of evidence demonstrated that liver stiffness measurement significantly correlates with liver fibrosis.
In 2011 a new parameter has been introduced named Controlled Attenuation Parameter (CAP™). CAP™ is a measure of ultrasound attenuation developed to assess steatosis. With CAP™, Fibroscan® can help assessing both liver fibrosis and steatosis at ounce.
In this paper the principle of CAP will be explained. Advantages and limitation of all techniques assessing liver steatosis will be explained. A comprehensive literature review of the CAP publications will be then given in particular to appraise its diagnostic performances. Eventually, we will present how these performances can be enhanced using a dedicated liver guidance tool.